marketing rights, including pergolide mesylate
tablets, bioequivalent to Lilly's Permax; nifedipine extended-release tablets 90 mg, equivalent to Bayer Corp.
Pergolide mesylate, a drug developed for human use under the brand name Permax by Eli Lilly, was voluntarily withdrawn from the market in August 2007, making it difficult for veterinarians to obtain the preparation for its common off-label use in veterinary practice.
The Material Safety Data Sheet for the chemical pergolide mesylate indicates it is hazardous in case of ingestion or inhalation, and cautions against ingesting or breathing the chemical's dust.
L) announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for pergolide mesylate tablets in .
Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risks that launch of pergolide mesylate tablets in .
L) today announced that it has entered into a settlement of patent litigation with Amarin Corporation plc which will allow IVAX to begin marketing pergolide mesylate, the generic equivalent of Permax(R), in early September.
IVAX previously announced that its ANDA for pergolide mesylate tablets in .
L) announced today it has received tentative approval from the FDA of its Abbreviated New Drug Application (ANDA) for pergolide mesylate
tablets in .
Food and Drug Administration has issued final approval for the company's ANDA for Pergolide Mesylate Tablets.
Pergolide Mesylate Tablets are the AB-rated generic equivalent of Eli Lilly and Company's Permax(R) Tablets, and are indicated as an adjunct treatment to Carbidopa/Levodopa in the management of the signs and symptoms of Parkinson's Disease.